It is an effective regulator of plasma triglyceride (TG) and HDL cholesterol (HDL-C) levels (Ajjemami et al., 2015), and genetic variants in APOA5 are strong predictors of hypertriglyceridemia-related cardiovascular risk (Ding et al., 2012). This evidence concerns the gene APOA5 and hypertriglyceridemia.